Marloes C. Broekmans
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 30, 2023
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies.
Journal: Cancers
Published: November 06, 2020
T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
Journal: Oncotarget
Published: October 09, 2020
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 12, 2019
Catecholamine excretion profiles identify clinical subgroups of neuroblastoma patients.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 27, 2018
A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma.
Journal: Nature communications
Published: July 19, 2018
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
Journal: Expert review of clinical immunology
Published: February 22, 2018
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 13, 2017
Neuroblastoma is composed of two super-enhancer-associated differentiation states.
Journal: Nature genetics
Published: December 19, 2016
Last Updated: 09/26/2026